首页> 外文期刊>Journal of thrombosis and haemostasis: JTH >A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers.
【24h】

A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers.

机译:与最高分子量的von Willebrand因子多聚体丧失相关的新型2A型(第II组)von Willebrand疾病突变(L1503Q)。

获取原文
获取原文并翻译 | 示例
           

摘要

Type 2A von Willebrand disease (VWD) is characterized by decreased platelet-dependent function of von Willebrand factor (VWF) associated with an absence of high-molecular-weight multimers. In this study, sequence analysis of the VWF gene from a Type 2A VWD patient showed a novel, heterozygous T-->A transversion at nucleotide 4510, resulting in the non-conservative substitution of L1503Q in the mature VWF subunit. This substitution, which was not found in 55 unrelated normal individuals, was reproduced by in vitro site directed mutagenesis of a full-length VWF cDNA and was subsequently expressed in COS-7 cells. The corresponding recombinant mutant VWF protein was partially retained in COS-7 cells yet the full spectrum of multimers was observed, suggesting that the absence of the highest molecular weight multimers results from increased proteolysis. The recombinant mutant VWF protein was digested with the ADAMTS13 protease from VWF-depleted plasma and the aberrant VWF multimer pattern was observed. Theseresults suggest that the L1503Q substitution induces a conformational change in the VWF protein, which increases the protein's susceptibility to proteolysis. A three-dimensional model of the A2 domain demonstrates that the L1503Q mutation and the physiological proteolytic cleavage site for ADAMTS13 (Y(1605)-M(1606)) are localized close together in two adjacent parallel beta-sheets. The mutation L1503Q does not significantly disrupt the conformation of the protein; thus the subtle loss of multimers in this patient may be due to altered interactions with the ADAMTS13 protease.
机译:2A型von Willebrand病(VWD)的特征是与缺乏高分子量多聚体相关的von Willebrand因子(VWF)的血小板依赖性功能降低。在这项研究中,对来自2A型VWD患者的VWF基因的序列分析显示,在核苷酸4510处出现了一种新型的,杂合的T-> A转换,导致成熟VWF亚基中L1503Q的非保守取代。通过全长VWF cDNA的体外定点诱变重现了在55个无关的正常个体中未发现的这种取代,随后在COS-7细胞中表达。相应的重组突变型VWF蛋白部分保留在COS-7细胞中,但观察到多聚体的全谱图,表明不存在最高分子量的多聚体是由于蛋白水解作用增加。重组突变体VWF蛋白用ADAMTS13蛋白酶从耗尽VWF的血浆中消化,观察到异常的VWF多聚体模式。这些结果表明,L1503Q取代诱导了VWF蛋白的构象变化,从而增加了该蛋白对蛋白水解的敏感性。 A2域的三维模型表明,ADAMTS13(Y(1605)-M(1606))的L1503Q突变和生理蛋白水解切割位点紧密相邻地位于两个相邻的平行β-折叠中。 L1503Q突变不会显着破坏蛋白质的构象。因此,该患者中多聚体的微弱损失可能是由于与ADAMTS13蛋白酶相互作用的改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号